Premium
Ni(II) alters the NFκB signaling pathway in monocytic cells
Author(s) -
Li Lei,
Wataha John C.,
Cate Casey,
Zhang Hai,
DiJulio Dennis,
Chung Whasun O.
Publication year - 2012
Publication title -
journal of biomedical materials research part b: applied biomaterials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.665
H-Index - 108
eISSN - 1552-4981
pISSN - 1552-4973
DOI - 10.1002/jbm.b.32655
Subject(s) - secretion , cytokine , nf κb , lipopolysaccharide , interleukin 6 , tumor necrosis factor alpha , monocyte , microbiology and biotechnology , inflammation , chemistry , biology , signal transduction , immunology , endocrinology
Nickel‐based alloys are used for dental restorations because of their strength, high moduli, and relatively low cost. However, these alloys corrode significantly in use, particularly in lower pH environments that are common under oral biofilms. Ni(II) corrosion products increase inflammatory cytokine secretion from activated monocytes, suggesting that nickel alloys may exacerbate inflammatory responses in adjacent periodontal tissues caused by dental plaque. Because inflammatory cytokine secretion is regulated in part by the NFκB signaling pathway, our goal in the current work was to determine whether Ni(II) altered cellular levels or nuclear localization of NFκB‐family subtypes. THP1 monocytes were exposed to Ni(II) for 72 h, and activated with lipopolysaccharide for the last 30 min to 6 h. Secretion of IL6 and TNFα were measured using ELISA, and NFκB levels and localization was measured using SDS‐PAGE with immunoblots and digital analysis. We observed that Ni(II) did not alter the levels of secreted TNFα from activated monocytes, but increased secreted IL6 levels about 30% over controls. Ni(II) did not alter whole‐cell levels of any NFκB subtype, but increased nuclear persistance of p65 and c‐Rel. Our results suggest that Ni(II) may increase inflammatory cytokine secretion by increasing nuclear localization of some NFκB subtypes. Further studies should be done to determine the prominence of this mechanism in clinical environments. © 2012 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 2012.